Immutep (IMMP) Non Operating Interest Expenses (2011 - 2015)
Immutep's (IMMP) quarterly Non Operating Interest Expenses came in at -$205.0 in Q2 2015, up 100.0% on a YoY basis from -$102.5 in Q2 2014, and up 100.0% quarter-over-quarter from -$12.0 million in Q2 2014.
Analysis
Immutep (IMMP) Non Operating Interest Expenses (2011 - 2015) Analysis & Trends
Immutep (IMMP) has reported Non Operating Interest Expenses for 4 consecutive years, with -$205.0 the latest figure, recorded in Q2 2015.
- For the quarter ending Q2 2015, Non Operating Interest Expenses rose 100.0% year-over-year to -$205.0; the trailing twelve-month figure through Jun 2016 stood at -$26.8 million (up 45.43% YoY), and the FY2026 full-year result was -$48162.3, down 102.82% from the prior year.
- Non Operating Interest Expenses rose to -$205.0 in Q2 2015 per IMMP's latest filing, from -$12.0 million in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at -$205.0 in Q2 2015 and bottomed at -$22.3 million in Q2 2011.
- Historically, Non Operating Interest Expenses has averaged -$12.3 million across 4 years, with a median of -$13.4 million in 2013.
- The sharpest annual moves came in 2014 and 2015: Non Operating Interest Expenses gained 18.76% in 2014, then soared 100.0% in 2015.
- Over 4 years, Non Operating Interest Expenses stood at -$22.3 million in 2011, then jumped by 33.73% to -$14.8 million in 2013, then grew by 18.76% to -$12.0 million in 2014, then jumped by 100.0% to -$205.0 in 2015.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$205.0, -$12.0 million, and -$14.8 million for Q2 2015, Q2 2014, and Q2 2013 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Immutep | 51.68 Mn | 51.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2015 | -205.00 |
| Jun 30, 2014 | -12.01 Mn |
| Jun 30, 2013 | -14.79 Mn |
| Jun 30, 2011 | -22.31 Mn |